{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:54:52Z","timestamp":1793699692205,"version":"4.5.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency\/hyper IgD syndrome (MKD\/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still\u2019s disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1\u03b1, IL-1\u03b2, IL-1Ra, IL-18, IL-36Ra, IL-36\u03b1, IL-37, IL-36\u03b2, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.<\/jats:p>","DOI":"10.3389\/fimmu.2020.619257","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:11:04Z","timestamp":1612300264000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives"],"prefix":"10.3389","volume":"11","author":[{"given":"Hana","family":"Malcova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Strizova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Milota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Striz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sediva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dita","family":"Cebecauerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.12.003","article-title":"Autoinflammatory diseases: State of the art","volume":"48","author":"Georgin-Lavialle","year":"2019","journal-title":"Presse Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10067-014-2721-0","article-title":"The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1466-y","article-title":"Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists\u2019 lens","volume":"11","author":"Cattalini","year":"2016","journal-title":"Intern Emerg Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.07.016","article-title":"Amyloidosis in autoinflammatory syndromes","volume":"12","author":"Obici","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.005","article-title":"Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.004","article-title":"Systemic-onset juvenile idiopathic arthritis","volume":"15","author":"Cimaz","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic Juvenile Idiopathic Arthritis","volume":"65","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12334","article-title":"Kawasaki disease: a comprehensive review of treatment options","volume":"40","author":"Patel","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"B9","unstructured":"ClinicalTrials."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1042\/CS20170098","article-title":"Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations","volume":"131","author":"Striz","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"B14","unstructured":""},{"key":"B15","unstructured":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still\u2019s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4161\/mabs.3.1.13989","article-title":"XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases","volume":"3","author":"Owyang","year":"2011","journal-title":"MAbs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kluck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis","volume":"10","author":"Sanchez-Fernandez","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-020-0104-x","article-title":"Inflammasome inhibition under physiological and pharmacological conditions","volume":"21","author":"Caseley","year":"2020","journal-title":"Genes Immun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19092714","article-title":"Peptides as Therapeutic Agents for Inflammatory-Related Diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MR0720-513R","article-title":"NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma","volume":"108","author":"McKee","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","first-page":"R202","DOI":"10.1186\/ar3535","article-title":"Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study","volume":"13","author":"Kone-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209031","article-title":"Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study","volume":"76","author":"Gattorno","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1416::AID-ART236>3.0.CO;2-6","article-title":"The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease","volume":"44","author":"Brik","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.38777","article-title":"Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study","volume":"66","author":"Brik","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-015-0765-4","article-title":"Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever","volume":"17","author":"Gul","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.987437","article-title":"Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients","volume":"25","author":"Basaran","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","article-title":"Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever","volume":"38","author":"Cetin","year":"2015","journal-title":"Inflammation"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1559488","article-title":"Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients","volume":"30","author":"Gulez","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2772-2","article-title":"Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis","volume":"35","author":"Ozcakar","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa205","article-title":"A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever","volume":"59","author":"Kuemmerle-Deschner","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3293-2","article-title":"Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents","volume":"35","author":"Eroglu","year":"2015","journal-title":"Rheumatol Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13891","article-title":"Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience","volume":"23","author":"Kurt","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.39995","article-title":"Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.39763","article-title":"The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry","volume":"68","author":"Ter Haar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.40146","article-title":"Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome","volume":"69","author":"Arostegui","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1442639","article-title":"National survey of Japanese patients with mevalonate kinase deficiency reveals distinctive genetic and clinical characteristics","volume":"29","author":"Tanaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318190cfb7","article-title":"Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome","volume":"87","author":"van der Hilst","year":"2008","journal-title":"Med (Baltimore)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118790","article-title":"Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever","volume":"108","author":"Hoffman","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22206","article-title":"Challenges in diagnosing Muckle-Wells syndrome: identifying two distinct phenotypes","volume":"66","author":"Kuemmerle-Deschner","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S114447","article-title":"Muckle-Wells syndrome: clinical perspectives","volume":"9","author":"Tran","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-016-0542-8","article-title":"Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review","volume":"11","author":"Finetti","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215048","article-title":"Classification criteria for autoinflammatory recurrent fevers","volume":"78","author":"Gattorno","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/039463201102400402","article-title":"Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes","volume":"24","author":"Cantarini","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207546","article-title":"Recommendations for the management of autoinflammatory diseases","volume":"74","author":"ter Haar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1-receptor antagonist in the Muckle-Wells syndrome","volume":"348","author":"Hawkins","year":"2003","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel269","article-title":"Clinical and genetic characterization of Italian patients affected by CINCA syndrome","volume":"46","author":"Caroli","year":"2007","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0500-8","article-title":"A variant Muckle-Wells syndrome with a novel mutation in CIAS1 gene responding to anakinra","volume":"22","author":"Dalgic","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem318","article-title":"New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes","volume":"47","author":"Maksimovic","year":"2008","journal-title":"Rheumatol (Oxford)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40463-018-0256-0","article-title":"Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature","volume":"47","author":"Marchica","year":"2018","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B72","article-title":"Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss","volume":"9","author":"Stew","year":"2013","journal-title":"B-ENT"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/art.23261","article-title":"Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome","volume":"58","author":"Yamazaki","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2722-z","article-title":"Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome","volume":"33","author":"Rigante","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B76","article-title":"The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review","volume":"31","author":"Magnotti","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12521","article-title":"Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant","volume":"18","author":"Cantarini","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2556-8","article-title":"Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate","volume":"34","author":"Lopalco","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s002960100103","article-title":"Arthritis in familial Mediterranean fever","volume":"20","author":"Uthman","year":"2001","journal-title":"Rheumatol Int"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3715-5","article-title":"Familial Mediterranean fever, review of the literature","volume":"36","author":"Alghamdi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2916-z","article-title":"Non-canonical manifestations of familial Mediterranean fever: a changing paradigm","volume":"34","author":"Rigante","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13023-019-1201-7","article-title":"Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)","volume":"14","author":"El Hasbani","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2020.03.069","article-title":"Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study","volume":"311","author":"Lazaros","year":"2020","journal-title":"Int J Cardiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11886-020-01308-y","article-title":"Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020","volume":"22","author":"Tombetti","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160518","article-title":"Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever","volume":"44","author":"Laskari","year":"2017","journal-title":"J Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1194510","article-title":"Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever","volume":"27","author":"Kucuksahin","year":"2017","journal-title":"Mod Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.02.001","article-title":"Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases","volume":"62","author":"Cakan","year":"2020","journal-title":"Turk J Pediatr"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa121","article-title":"Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry","volume":"59","author":"Sag","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/9691","article-title":"Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome","volume":"22","author":"Houten","year":"1999","journal-title":"Nat Genet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes097","article-title":"Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency","volume":"51","author":"Galeotti","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review","volume":"72","author":"Ter Haar","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.619257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:11:08Z","timestamp":1612300268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.619257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2020.619257"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.619257","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"619257"}}